The math is compelling but looking at SAGE, when I check 13F holdings, I see no positions held by any of the major biotech focused HFs such as RA, Baker, Orbimed, etc. STOK is about the same but Baker has a tiny (0.55% of AUM) position. Possibly concerning?
Also, this might help you find other bargains; pull up the 13Fs on the above menti…
The math is compelling but looking at SAGE, when I check 13F holdings, I see no positions held by any of the major biotech focused HFs such as RA, Baker, Orbimed, etc. STOK is about the same but Baker has a tiny (0.55% of AUM) position. Possibly concerning?
Also, this might help you find other bargains; pull up the 13Fs on the above mentioned HFs, sort positions by current price, low to high, and take a look at all the cheap ones. Baker for example has 26 positions trading < 5 (based on 12/31/24 close) and eye-balling it, looks like on average, prices are down ~at least 75% from their estimated cost.
The math is compelling but looking at SAGE, when I check 13F holdings, I see no positions held by any of the major biotech focused HFs such as RA, Baker, Orbimed, etc. STOK is about the same but Baker has a tiny (0.55% of AUM) position. Possibly concerning?
Also, this might help you find other bargains; pull up the 13Fs on the above mentioned HFs, sort positions by current price, low to high, and take a look at all the cheap ones. Baker for example has 26 positions trading < 5 (based on 12/31/24 close) and eye-balling it, looks like on average, prices are down ~at least 75% from their estimated cost.